Lung Cancer

The FDA has granted breakthrough device designation to Serial CTRS for risk prognosis in non–small cell lung cancer.

The Canning Thoracic Institute became the highest-volume lung transplant center in the US and achieved the shortest wait time for a lung transplant.

Tina Cascone, MD, PhD, discusses the efficacy and safety of neoadjuvant durvalumab plus novel agents or chemotherapy in resectable NSCLC.

The FDA has granted orphan drug designation to 225Ac-satoreotide for patients with small cell lung cancer.

Leveraging synthetic lethal approaches in lung cancer with new targets and agents may be a promising avenue of investigation.

The European Commission has approved serplulimab in combination with carboplatin and etoposide for the frontline treatment of adult patients with ES-SCLC.

Manish R. Patel, MD, and Gottfried E. Konecny, MD, detail findings from studies evaluating CLDN6-directed agents that showed signals of promising efficacy and tolerability.

The variety of nonclassical EGFR mutations in NSCLC necessitates the development of unique treatment strategies based on individual mutational profiles.

THIO plus cemiplimab generated a potential survival benefit in pretreated advanced non–small cell lung cancer.

The EMA’s CHMP has issued a positive opinion supporting the approval of subcutaneous amivantamab in EGFR-mutated NSCLC.

KEAP1 and STK11 have emerged as potential biomarkers of response to immuno-oncology combinations in frontline NSCLC.

The CHMP has recommended approval for durvalumab in limited-stage small cell lung cancer following platinum-based chemoradiation.

Tarek Mekhail, MD, MSc, FRCSI, FRCSEd, discusses a case study of a patient with early-stage, nonmetastatic lung adenocarcinoma.

Benjamin P. Levy, MD, discusses the current clinical and developmental statuses of several ADCs for patients with non–small cell lung cancer.

Misty Shields, MD, PhD, provides a comprehensive overview of key updates in. the management of limited-stage small cell lung cancer.

Russell Hales, MD, discusses clinical data that challenge the use of post-operative radiotherapy in patients with non–small cell lung cancer.

Estelamari Rodriguez, MD, MPH, discusses a case study of a patient with non–small cell lung cancer harboring an EGFR L858R mutation and a TP53 mutation.

Melissa L. Johnson, MD, discusses the evolution of immunotherapy approaches beyond PD-1 inhibition in lung cancer.

Walter J. Curran, MD, discusses the evolving use of radiotherapy in small cell cancer and data supporting its optimal use.

Misty D. Shields, MD, PhD, discusses the implications of the ADRIATIC trial of adjuvant therapy with durvalumab vs placebo in patients with LS-SCLC.

Corey J. Langer, MD, discusses how the use of adjuvant immunotherapy has affected the resectable NSCLC treatment paradigm.

Alexander I. Spira MD, PhD, FACP, FASCO, details the next steps for amivantamab in patients with EGFR–mutated locally advanced non–small cell lung cancer.

The REZILIENT1 study of zipalertinib in pretreated patients with NSCLC harboring EGFR exon 20 insertion mutations met its primary end point of ORR.

Findings from an oncogene overlap study in NSCLC support the potential clinical impact of high-level amplification of MET, HER2, and KRAS defined by NGS.

Alexander Watson, MD, DPhil, FRCPC, explains how the relationship between driver positivity and amplification status affects same-gene alteration enrichment.